enGene Therapeutics reported net income of -$32.71M for the quarter ended Jul 2026. This income statement covers 16 quarters of results from Oct 2022 through Jul 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Oct2022 | Jan2023 | Apr2023 | Jul2023 | Oct2023 | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 | Jul2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.67M | 0.67M | 0.70M | 0.70M | 0.69M | 23.20M | 44.16M | 44.22M | 37.78M | 50.98M | 51.07M | 51.11M | 52.02M | 66.99M | 66.99M | 67.02M |
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 3.67M | 3.21M | 3.90M | 5.67M | 5.64M | 9.86M | 11.55M | 11.27M | 19.97M | 20.21M | 22.57M | 31.72M | 22.25M | 22.20M | 20.09M | |
| Selling, General & AdministrativeSG&A | 0.96M | 1.52M | 2.35M | 4.77M | 5.13M | 7.46M | 5.21M | 6.18M | 6.64M | 6.92M | 7.37M | 7.76M | 8.93M | 9.77M | 13.92M | |
| Restructuring CostsRestructuring | 3.03M | 2.49M | 3.79M | 4.09M | 3.09M | |||||||||||
| Other Operating ExpensesOther Opex | -3.03M | -2.49M | -3.79M | -4.09M | -3.09M | |||||||||||
| Operating ExpensesOpex | 4.63M | 4.74M | 6.25M | 10.44M | 10.77M | 17.31M | 16.76M | 17.45M | 26.61M | 27.12M | 29.95M | 39.48M | 31.18M | 31.97M | 34.01M | |
| Operating IncomeOp. Inc | -4.63M | -4.74M | -6.25M | -10.44M | -10.77M | -17.31M | -16.76M | -17.45M | -26.61M | -27.12M | -29.95M | -39.48M | -31.18M | -31.97M | -34.01M | |
| EBIT | -4.63M | -4.74M | -6.25M | -10.44M | -10.77M | -17.31M | -16.76M | -17.45M | -26.61M | -27.12M | -29.95M | -39.48M | -31.18M | -31.97M | -34.01M | |
| Non-operating items | ||||||||||||||||
| Non Operating Interest Expenses | 1.18M | 1.18M | 1.44M | 1.16M | 0.56M | 0.73M | 0.75M | 0.76M | 0.75M | 0.73M | 0.76M | 0.75M | 0.73M | 0.74M | 0.84M | |
| Interest & Investment IncomeInt & Inv Inc | 0.17M | 0.15M | 0.39M | 0.41M | 1.02M | 2.98M | 3.38M | 3.02M | 2.73M | 2.49M | 2.23M | 1.98M | 2.74M | 2.66M | 2.40M | |
| Other Non Operating IncomeOther Non Op Inc. | -0.28M | 0.20M | -0.44M | 0.40M | -0.37M | 0.09M | -0.05M | 0.04M | -0.20M | -0.28M | -0.12M | -0.49M | -0.18M | -0.04M | ||
| Non Operating IncomeNon Op. Inc. | -2.79M | -0.55M | 1.53M | -72.04M | 0.03M | 2.35M | 2.58M | 2.17M | 2.02M | 1.55M | 1.20M | 1.10M | 1.43M | 1.74M | 1.51M | |
| Net income details | ||||||||||||||||
| EBT | -7.42M | -5.28M | -4.72M | -82.48M | -10.74M | -14.96M | -14.18M | -15.28M | -24.60M | -25.57M | -28.75M | -38.38M | -29.75M | -30.23M | -32.50M | |
| Tax ProvisionsTaxes | 0.02M | -0.03M | 0.02M | -0.03M | 0.02M | 0.02M | 0.24M | 0.24M | -0.50M | |||||||
| Profit After TaxPAT | -7.42M | -5.28M | -5.99M | -83.59M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -29.23M | -37.88M | -29.75M | -30.53M | -32.71M | |
| Income from Continuing OperationsIncome (Continuing) | -7.42M | -5.28M | -4.72M | -82.50M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M | -32.50M | |
| Consolidated Net IncomeConsol Net Inc. | -7.42M | -5.28M | -4.72M | -82.50M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M | -32.50M | |
| Income towards Parent CompanyParent Net Inc | -7.42M | -5.28M | -4.72M | -82.50M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M | -32.50M | |
| Net Income towards Common StockholdersNet Income | -7.42M | -5.28M | -4.72M | -82.50M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M | -32.50M | |
| Additional items | ||||||||||||||||
| EPS (Basic) | -11.39 | -7.61 | -6.73 | -119.11 | -0.46 | -0.38 | -0.32 | -0.40 | -0.48 | -0.51 | -0.57 | -0.74 | -0.44 | -0.43 | -0.47 | |
| EPS (Diluted) | -11.39 | -7.61 | -6.73 | -119.11 | -0.46 | -0.38 | -0.32 | -0.40 | -0.48 | -0.51 | -0.57 | -0.74 | -0.44 | -0.43 | -0.47 | |
| Shares Outstanding | 0.66M | 0.65M | 0.69M | 0.70M | 0.69M | 23.20M | 39.44M | 44.17M | 37.78M | 50.98M | 51.02M | 51.10M | 51.12M | 67.26M | 69.72M | 69.73M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.66M | 0.65M | 0.69M | 0.70M | 0.69M | 23.20M | 39.44M | 44.17M | 37.78M | 50.98M | 51.02M | 51.10M | 51.12M | 67.26M | 69.72M | 69.73M |
| EBITDA | -4.63M | -4.74M | -6.25M | -10.44M | -10.77M | -17.31M | -16.76M | -17.45M | -26.61M | -27.12M | -29.95M | -39.48M | -31.18M | -31.97M | -34.01M | |
| Interest ExpensesInt Expense | 1.18M | 1.18M | 1.44M | 1.16M | 0.56M | 0.73M | 0.75M | 0.76M | 0.75M | 0.73M | 0.76M | 0.75M | 0.73M | 0.74M | 0.84M | |
| Tax Rate | -0.02 | 0.28 | -0.14 | 0.20 | -0.12 | -0.07 | -0.94 | -0.83 | 1.30 |